A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age

A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age

Inactivated influenza vaccines efficacy is variable and often poor. We conducted a phase 1 trial (NCT02188810), to assess the safety and immunogenicity of a novel nanoparticle Toll-like receptor 7/8 agonist adjuvant (Papaya Mosaic Virus) at different dose levels combined with trivalent influenza vac...

Full description

Bibliographic Details
Main Authors: Joanne Langley, Elodie Pastural, Scott Halperin, Shelly McNeil, May ElSherif, Donna MacKinnon-Cameron, Lingyun Ye, Cécile Grange, Valérie Thibodeau, Jean-François Cailhier, Rejean Lapointe, Janet McElhaney, Luis Martin, Marilène Bolduc, Marie-Eve Laliberté-Gagné, Denis Leclerc, Pierre Savard
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Vaccines
Subjects:
influenza vaccines
immunogenicity
adjuvants
Online Access:https://www.mdpi.com/2076-393X/8/3/393

Similar Items

Similar Items